Sat Kartar Life Ltd

NSE: SATKARTAR · Pharmaceuticals & Biotechnology · 49 announcements

Sat Kartar Life Ltd news stories on ALFA NewsRead the news →

Share price: ₹161.25
Market cap: ₹254.7 Cr
Revenue (annual): ₹200.7 Cr
Net profit (annual): ₹17.10 Cr
P/E (TTM): 14.9×Sector 47.4×
Promoter holding: 63.62%
FII holding: 0.13%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

19 Apr 2026 09:35 IST NSE

Sat Kartar Life Acquisition Worth ₹1.21 Cr

Sat Kartar Shopping Limited is acquiring the remaining stake in Plantomed Neutraceuticals Private Limited for ₹1.21 Crore to make it a wholly-owned subsidiary. The acquisition of the Ayurveda healthcare company aims to consolidate brands and expand the product portfolio. The transaction is expected to be completed by May 15, 2026.

Value: ₹1.21 Cr
Execution: 15-05-2026

Read the filing ↗

19 Apr 2026 09:34 IST NSE

Acquisition

Sat Kartar Life Acquisition Worth ₹1.21 Cr

Sat Kartar Shopping Limited approved the acquisition of a further 24% stake in Plantomed Neutraceuticals Private Limited for ₹1.21 Crore. This transaction will increase the company's control to 100%, making the target a wholly-owned subsidiary. The acquisition aims to consolidate branding and expand the company's Ayurveda and wellness product portfolio by May 2026.

Value: ₹1.21 Cr
Execution: 15-05-2026

Read the filing ↗

18 Apr 2026 18:59 IST NSE

Acquisition

Sat Kartar Life Acquisition Worth ₹1.21 Cr

Sat Kartar Life Limited approved the acquisition of an additional 24% stake in Plantomed Nutraceuticals Private Limited for ₹1.21 Crore. The transaction will make the target a wholly-owned subsidiary, aiding brand consolidation and aligning operations with the company's long-term vision. The deal is expected to close by May 15, 2026.

Value: ₹1.21 Cr
Execution: Expected to close by 15th May, 2026

Read the filing ↗